达克珠单抗(Daclizumab) - 药物靶点：IL2RA_在研适应症：复发-缓解型多发性硬化，多发性硬化症，器官移植排斥_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

DAC HYP、Dacliximab、Daclizumab (USAN/INN)

+ [14]

靶点

IL2RA

作用方式

抑制剂

作用机制

IL2RA抑制剂(白细胞介素-2受体α链抑制剂)

治疗领域

免疫系统疾病神经系统疾病其他疾病

在研适应症

复发-缓解型多发性硬化多发性硬化症器官移植排斥

非在研适应症

同种异体移植排斥反应心脏移植排斥反应溃疡性结肠炎+ [4]

原研机构

AbbVie, Inc.

在研机构

Biogen, Inc.

F. Hoffmann-La Roche Ltd.

非在研机构

AbbVie, Inc.

Abbott Biotherapeutics Corp.

Biogen Idec Ltd.

+ [3]

权益机构

Abbott Biotherapeutics Corp.

上海雅培制药有限公司

Biogen, Inc.

最高研发阶段批准上市

首次获批日期

美国 (1997-12-10),

器官移植排斥

最高研发阶段(中国)-

特殊审评孤儿药 (美国)

登录后查看时间轴

结构/序列

Sequence Code 143514H

来源: *****

Sequence Code 143753L

来源: *****

关联

82

项与达克珠单抗相关的临床试验

ChiCTR2600133108

/ Not yet recruiting临床3期IIT

A randomized, open-label, parallel-controlled, multicenter phase III clinical study of CD25 monoclonal antibody in preventing acute graft-versus-host disease after haploidentical hematopoietic stem cell transplantation

开始日期2026-05-01

申办/合作机构

华中科技大学同济医学院附属协和医院

NCT07689630

/ Recruiting临床3期IIT

A Randomized, Open-Label, Parallel-Controlled, Multicenter Phase III Clinical Trial of Anti-CD25 Monoclonal Antibody Versus Methotrexate for the Prevention of Acute Graft-Versus-Host Disease After Haploidentical Hematopoietic Stem Cell Transplantation

Acute graft-versus-host disease remains a major complication after haploidentical hematopoietic stem cell transplantation. Methotrexate is commonly used as part of graft-versus-host disease prophylaxis, but it may be associated with delayed hematopoietic recovery and transplant-related toxicities, including oral mucositis.
This is a prospective, multicenter, randomized, open-label, parallel-controlled Phase III clinical trial designed to evaluate an anti-CD25 monoclonal antibody regimen compared with methotrexate for the prevention of acute graft-versus-host disease after haploidentical hematopoietic stem cell transplantation. Eligible patients with hematologic malignancies scheduled to undergo haploidentical allogeneic hematopoietic stem cell transplantation will be randomly assigned in a 1:1 ratio to receive either methotrexate-based prophylaxis or anti-CD25 monoclonal antibody-based prophylaxis, in combination with standard graft-versus-host disease prophylaxis including anti-thymocyte globulin, calcineurin inhibitor, and mycophenolate mofetil.
The primary objective is to compare 12-month graft-versus-host disease-free, relapse-free survival between the two groups. Secondary objectives include comparison of acute graft-versus-host disease, chronic graft-versus-host disease, oral mucositis, hematopoietic recovery, cytomegalovirus and Epstein-Barr virus reactivation, infection, relapse, non-relapse mortality, overall survival, and leukemia-free survival.

开始日期2026-05-01

申办/合作机构-

NCT02881567

/ Terminated临床3期

A Phase 3b, 12-month, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of BIIB019, Daclizumab, in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab (SUSTAIN)

The primary objective of the study is to evaluate the effects of treatment with daclizumab on the proportion of participants relapse-free at 6 months in Relapsing-Remitting Multiple Sclerosis (RRMS) participants, who switched from treatment with natalizumab to daclizumab due to safety concerns. The secondary objectives of this study in this study population are to evaluate the effects of daclizumab on the following: 1) Multiple Sclerosis (MS) relapse activity including the annualized relapse rate (ARR) and the proportion of participants experiencing relapses requiring hospitalization and/or steroid treatment; 2) MS-related outcomes measured using magnetic resonance imaging (MRI); 3) Safety and tolerability in participants previously treated with natalizumab.

开始日期2017-04-18

申办/合作机构

Biogen, Inc.

[+1]

100 项与达克珠单抗相关的临床结果

登录后查看更多信息

100 项与达克珠单抗相关的转化医学

登录后查看更多信息

100 项与达克珠单抗相关的专利（医药）

登录后查看更多信息

749

项与达克珠单抗相关的文献（医药）

2026-05-01·JOURNAL OF NEUROLOGY

Efficacy and safety of monoclonal antibodies in the treatment of relapsing remitting multiple sclerosis: a systematic review

Review

作者: Fanlo-Villacampa, Ana ; Avedillo-Salas, Ana ; Vicente-Romero, Jorge ; Martínez, Laura Baeza

Abstract:

Introduction:

In relapsing–remitting multiple sclerosis (RRMS), conventional immunomodulatory and immunosuppressive therapies are widely used. However, in many cases, optimal control of inflammatory activity and disease progression is not achieved, which has led to the use of biological drugs such as monoclonal antibodies that act specifically on key components of the immune system. The aim was to evaluate the efficacy and safety of monoclonal antibodies compared to other drugs or placebo in adult patients with RRMS.

Methods:

A systematic review was performed based on randomized, double-blind, phase III controlled clinical trials published between 2012 and 2025 in the PubMed, Cochrane Library, and Web of Science databases, assessing efficacy and safety in adult patients with RRMS. The review was carried out following the PICO methodology and PRISMA guidelines.

Results:

A total of 11 studies were included, evaluating 5 monoclonal antibodies: alemtuzumab, daclizumab, ocrelizumab, ofatumumab, and ublituximab. These therapies showed superior efficacy compared to conventional treatments in reducing the annual relapse rate, MRI inflammatory activity and MRI activity, particularly in patients with highly active disease. However, effects on disability progression were heterogeneous across trials and not consistently significant. In addition, decreases in biomarkers of axonal damage were observed. Nevertheless, relevant adverse effects were identified, including infections, autoimmune reactions, hepatic and cutaneous toxicity, whose incidence varies depending on the drug, requiring close clinical monitoring.

Conclusions:

Monoclonal antibodies are an effective option in RRMS, with clinical and radiological benefits superior to those of conventional treatments. Their use requires individualized assessment and close follow-up due to the risk of adverse effects, especially in high-risk patients.

2026-04-01·INTERNATIONAL IMMUNOPHARMACOLOGY

Single-cell transcriptomic mendelian randomization and co-localization reveal immune-mediated regulatory mechanisms and drug targets in atopic dermatitis

Article

作者: Xiang, Niu ; Gong, Ting ; Tong, Zequn ; Ji, Chao ; Cheng, Bo ; Li, Weixing ; Xu, Qiuyun ; Zou, Ying ; Zhao, XiaoYan ; Zhou, Kunli ; Cai, Liangqi

BACKGROUND:

Atopic dermatitis (AD) is a chronic inflammatory skin condition with increasing prevalence; however, the underlying immune mechanisms remain poorly understood. Precision therapeutics have shown promise, yet significant unmet clinical needs remain. Single-cell expression quantitative trait loci (sc-eQTL) combined with genome-wide association studies (GWAS) and mendelian randomization (MR) can provide cell-type-specific causal evidence for immune mechanisms in complex diseases METHODS: We integrated sc-eQTL data from 14 immune cell types (OneK1K cohort, n = 982) with AD GWAS summary statistics from FinnGen (n = 31,245) and GWAS Catalog (n = 22,474). We performed two-sample MR using inverse variance weighting and Wald ratio methods, with MR-Egger, MR-PRESSO, and Steiger directionality tests ensuring robustness. Co-localization analysis confirmed shared causal variants, and functional enrichment analyses explored candidate gene mechanisms.

RESULTS:

We identified 14 immune cell-specific hub genes (CD52, CD4 NC, IL2RA, TNF, HLA-DQB2, and others) with strong co-localization evidence (PP·H4 > 0.7). Enrichment analysis revealed significant clustering in MHC class II protein complexes and (e.g., HLA-DR, HLA-DP, HLA-DQ) and partially in TNF and MHC-I classes like HLAC. Pathway analysis indicated significant enrichment in immune-related pathways, including asthma and inflammatory bowel disease. Additionally, 46 drugs targeting these genes were identified, with 13 causal genes overlapping with known druggable targets, such as alemtuzumab (CD52), daclizumab (IL2RA), and TNF inhibitors.

CONCLUSIONS:

Our study provides genetic evidence supporting a causal role for immune cell-specific genes in AD susceptibility. The 14 hub genes and associated druggable targets establish a foundation for precision immunotherapy development in AD.

2026-01-01·Experimental and Clinical Transplantation

No Association of Sex or Racial Factors With Outcomes in Adult Intestine-Only Transplant: A United Network for Organ Sharing Database Analysis.

Article

作者: Li, Meng-Hao ; Tupper, Connor J ; Koizumi, Naoru ; Cogua, Laura M ; Ortiz, Jorge ; Faddoul, Giovanni

OBJECTIVES:

Adult intestine-only transplant is an uncommon procedure for intestinal failure. We assessed demographic factors associated with recipient mortality and graft failure rates in adult intestine-only transplant recipients.

MATERIALS AND METHODS:

Data for cases of adult intestine-only transplants diagnosed for the period 2004-2024 were collected from the United Network for Organ Sharing database. Demographic characteristics of recipients, mortality, and graft survival were evaluated among racial groups.

RESULTS:

A total of 896 transplants were included. Most were White (75.2%) and were female (56.3%). There were no differences in graft failure or recipient mortality by race/ethnicity or sex. Race/ethnicity was not associated with graft survival for adult intestine-only transplant. Recipient mortality was greater with older recipients (hazard ratio = 1.022; P = .007). Basiliximab/daclizumab was associated with a higher mortality rate (hazard ratio = 1.001; P < .001). There were no racial disparities and no differences in regimens for induction immunosuppression or maintenance immunosuppression with regard to recipient mortality or graft failure.

CONCLUSIONS:

Recipient age and basiliximab/daclizumab may significantly influence adult intestine-only transplant recipient survival but not graft outcomes.

54

项与达克珠单抗相关的新闻（医药）

2026-09-18

·今日头条

山东第一医科大学附属省立医院举办第八十八期省医精诚学术论坛

9月14日，山东第一医科大学附属省立医院（山东省立医院）第八十八期省医精诚学术论坛在中心院区仁和楼第二会议室举办。本次论坛特邀美国西达赛奈医学中心蒋典华教授作专题讲座，呼吸与危重症医学科负责人刘毅教授主持会议，院内相关领域的专家学者参与学习。蒋典华教授是美国西达赛奈医学中心肺纤维化研究中心主任，医学系教授、生物医学科学系教授，担任《Journal of Respiratory Biology and Translational Medicine》主编、《Cell Investigation》副主编以及多个国际期刊编委。他长期致力于肺纤维化发病机制及转化研究，聚焦肺泡祖细胞衰老、干细胞微环境紊乱及代谢重编程在特发性肺纤维化（IPF）中的作用，首次揭示HAS2、TLR4、WNT7A、HER2等关键分子在纤维化中的调控机制，并推动抗PD-L1抗体治疗IPF的临床试验。他先后主持多项美国NIH R01及R35重点项目，在《Nature Medicine》《Journal of Clinical Investigation》《Science Translational Medicine》等知名期刊发表论文90余篇，总引用超15000次，H指数53，获得中国旅美科技协会服务卓越奖及资深研究者职业奖。蒋典华教授进行专题讲座蒋典华教授以《The Alveolar Stem Cell Niche in IPF: Vulnerable Seed in Hostile Soil》为题展开报告。他系统回顾了IPF治疗的发展历程，指出INSPIRE临床试验重塑了学界对IPF异质性的认知，推动以FVC下降作为临床获益的关键量化指标，直接促成了吡非尼酮和尼达尼布的成功获批。他深入阐释了AT2干细胞微环境在IPF中的失调机制，并介绍了从IPF生物学到AI辅助药物研发的转化路径。在治疗策略方面，他介绍了基因表达高通量筛选、基于疾病转录组图谱的AI药物发现以及针对特定靶点的AI虚拟筛选等完整流程，并分享了普芦卡必利和维鲁司特用于IPF的药物重定位策略，以及基于深度学习的从头药物发现平台——该平台通过匹配疾病转录组特征与化合物扰动特征，可以从超大规模化学库中筛选可逆转疾病表型的候选化合物。在交流环节，与会人员围绕肺纤维化相关类器官培养方法、标本选择策略、AI辅助研究方案设计、细胞治疗方向选择以及肿瘤靶向治疗前景等实际问题，与蒋典华教授展开深入探讨。蒋典华教授逐一解答，并结合自身研究经验分享了具体建议。本次学术论坛的成功举办，深化了医院相关科室医师和科研人员对肺纤维化精准诊疗等前沿方向的认识。未来，医院将持续举办高水平学术活动，邀请国内外顶尖专家分享前沿成果，助力医院学科建设、科研创新与人才培养协同发展。

2026-09-16

·山东省第一医科大学附属省立医院

山东第一医科大学附属省立医院举办第八十八期省医精诚学术论坛

9月14日，山东第一医科大学附属省立医院（山东省立医院）第八十八期省医精诚学术论坛在中心院区仁和楼第二会议室举办。本次论坛特邀美国西达赛奈医学中心蒋典华教授作专题讲座，呼吸与危重症医学科负责人刘毅教授主持会议，院内相关领域的专家学者参与学习。　　蒋典华教授是美国西达赛奈医学中心肺纤维化研究中心主任，医学系教授、生物医学科学系教授，担任《Journal of Respiratory Biology and Translational Medicine》主编、《Cell Investigation》副主编以及多个国际期刊编委。他长期致力于肺纤维化发病机制及转化研究，聚焦肺泡祖细胞衰老、干细胞微环境紊乱及代谢重编程在特发性肺纤维化（IPF）中的作用，首次揭示HAS2、TLR4、WNT7A、HER2等关键分子在纤维化中的调控机制，并推动抗PD-L1抗体治疗IPF的临床试验。他先后主持多项美国NIH R01及R35重点项目，在《Nature Medicine》《Journal of Clinical Investigation》《Science Translational Medicine》等知名期刊发表论文90余篇，总引用超15000次，H指数53，获得中国旅美科技协会服务卓越奖及资深研究者职业奖。蒋典华教授进行专题讲座　　蒋典华教授以《The Alveolar Stem Cell Niche in IPF: Vulnerable Seed in Hostile Soil》为题展开报告。他系统回顾了IPF治疗的发展历程，指出INSPIRE临床试验重塑了学界对IPF异质性的认知，推动以FVC下降作为临床获益的关键量化指标，直接促成了吡非尼酮和尼达尼布的成功获批。他深入阐释了AT2干细胞微环境在IPF中的失调机制，并介绍了从IPF生物学到AI辅助药物研发的转化路径。在治疗策略方面，他介绍了基因表达高通量筛选、基于疾病转录组图谱的AI药物发现以及针对特定靶点的AI虚拟筛选等完整流程，并分享了普芦卡必利和维鲁司特用于IPF的药物重定位策略，以及基于深度学习的从头药物发现平台——该平台通过匹配疾病转录组特征与化合物扰动特征，可以从超大规模化学库中筛选可逆转疾病表型的候选化合物。　　在交流环节，与会人员围绕肺纤维化相关类器官培养方法、标本选择策略、AI辅助研究方案设计、细胞治疗方向选择以及肿瘤靶向治疗前景等实际问题，与蒋典华教授展开深入探讨。蒋典华教授逐一解答，并结合自身研究经验分享了具体建议。　　本次学术论坛的成功举办，深化了医院相关科室医师和科研人员对肺纤维化精准诊疗等前沿方向的认识。未来，医院将持续举办高水平学术活动，邀请国内外顶尖专家分享前沿成果，助力医院学科建设、科研创新与人才培养协同发展。

2026-09-15

·山东第一医科大学附属省立医院

山东第一医科大学附属省立医院举办第八十八期省医精诚学术论坛

9月14日，山东第一医科大学附属省立医院（山东省立医院）第八十八期省医精诚学术论坛在中心院区仁和楼第二会议室举办。本次论坛特邀美国西达赛奈医学中心蒋典华教授作专题讲座，呼吸与危重症医学科负责人刘毅教授主持会议，院内相关领域的专家学者参与学习。蒋典华教授是美国西达赛奈医学中心肺纤维化研究中心主任，医学系教授、生物医学科学系教授，担任《Journal of Respiratory Biology and Translational Medicine》主编、《Cell Investigation》副主编以及多个国际期刊编委。他长期致力于肺纤维化发病机制及转化研究，聚焦肺泡祖细胞衰老、干细胞微环境紊乱及代谢重编程在特发性肺纤维化（IPF）中的作用，首次揭示HAS2、TLR4、WNT7A、HER2等关键分子在纤维化中的调控机制，并推动抗PD-L1抗体治疗IPF的临床试验。他先后主持多项美国NIH R01及R35重点项目，在《Nature Medicine》《Journal of Clinical Investigation》《Science Translational Medicine》等知名期刊发表论文90余篇，总引用超15000次，H指数53，获得中国旅美科技协会服务卓越奖及资深研究者职业奖。蒋典华教授进行专题讲座蒋典华教授以《The Alveolar Stem Cell Niche in IPF: Vulnerable Seed in Hostile Soil》为题展开报告。他系统回顾了IPF治疗的发展历程，指出INSPIRE临床试验重塑了学界对IPF异质性的认知，推动以FVC下降作为临床获益的关键量化指标，直接促成了吡非尼酮和尼达尼布的成功获批。他深入阐释了AT2干细胞微环境在IPF中的失调机制，并介绍了从IPF生物学到AI辅助药物研发的转化路径。在治疗策略方面，他介绍了基因表达高通量筛选、基于疾病转录组图谱的AI药物发现以及针对特定靶点的AI虚拟筛选等完整流程，并分享了普芦卡必利和维鲁司特用于IPF的药物重定位策略，以及基于深度学习的从头药物发现平台——该平台通过匹配疾病转录组特征与化合物扰动特征，可以从超大规模化学库中筛选可逆转疾病表型的候选化合物。在交流环节，与会人员围绕肺纤维化相关类器官培养方法、标本选择策略、AI辅助研究方案设计、细胞治疗方向选择以及肿瘤靶向治疗前景等实际问题，与蒋典华教授展开深入探讨。蒋典华教授逐一解答，并结合自身研究经验分享了具体建议。本次学术论坛的成功举办，深化了医院相关科室医师和科研人员对肺纤维化精准诊疗等前沿方向的认识。未来，医院将持续举办高水平学术活动，邀请国内外顶尖专家分享前沿成果，助力医院学科建设、科研创新与人才培养协同发展。供稿：科研部

100 项与达克珠单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D03639	达克珠单抗	L04AC01	DB00111

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
复发-缓解型多发性硬化	加拿大	Biogen, Inc.	2016-12-08
多发性硬化症	美国	Biogen, Inc.	2016-05-27
肾移植排斥反应	欧盟	Roche Registration Ltd.	1999-02-26
肾移植排斥反应	冰岛	Roche Registration Ltd.	1999-02-26
肾移植排斥反应	列支敦士登	Roche Registration Ltd.	1999-02-26
肾移植排斥反应	挪威	Roche Registration Ltd.	1999-02-26
器官移植排斥	美国	F. Hoffmann-La Roche Ltd.	1997-12-10

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
同种异体移植排斥反应	临床2期	美国	Roche Pharma AG	2003-10-01
心脏移植排斥反应	临床2期	美国	Roche Pharma AG	2003-10-01
溃疡性结肠炎	临床2期	美国	Abbott Biotherapeutics Corp.	2003-04-01
溃疡性结肠炎	临床2期	比利时	Abbott Biotherapeutics Corp.	2003-04-01
溃疡性结肠炎	临床2期	加拿大	Abbott Biotherapeutics Corp.	2003-04-01
持续性哮喘	临床2期	美国	Abbott Biotherapeutics Corp.	2001-09-01
1型糖尿病	临床2期	美国	Roche Pharma AG	2000-07-01
1型糖尿病	临床2期	美国	Abbott Biotherapeutics Corp.	2000-07-01
寻常性银屑病	临床2期	美国	Abbott Biotherapeutics Corp.	1997-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASH2025	N/A	-	17	Daclizumab	鹽窪醖糧膚鏇鹹蓋齋製(蓋膚餘夢壓襯鏇範觸鹽) = 簾繭觸憲願鏇窪醖鬱選簾觸襯廠鑰積範獵鹹鏇 (鬱廠願簾憲積獵製簾艱 ) 更多	积极	2025-12-06
EBMT2025	N/A	急性移植物抗宿主病	17	Daclizumab	淵獵鑰鬱範鬱蓋遞築蓋(製鏇壓壓淵醖艱齋鑰廠) = 鬱製範願簾淵鏇夢襯網簾齋鬱鑰餘顧蓋選醖顧 (餘鬱餘鹽簾膚製網網膚 ) 更多	积极	2025-03-30
ASH2024 人工标引	N/A	地中海贫血	169	Daclizumab + standard GvHD prophylaxis	淵構鬱鏇鏇餘醖壓餘構(觸遞鬱鏇鏇鹽糧壓築襯) = 艱窪廠繭構構鏇簾餘壓襯獵鹽製選齋繭餘窪積 (壓衊鏇夢窪廠齋鏇獵觸 ) 更多	积极	2024-12-07
ASH2024 人工标引	N/A	地中海贫血	169	Standard GvHD prophylaxis	淵構鬱鏇鏇餘醖壓餘構(觸遞鬱鏇鏇鹽糧壓築襯) = 顧膚觸窪範顧憲鏇範鬱襯獵鹽製選齋繭餘窪積 (壓衊鏇夢窪廠齋鏇獵觸 ) 更多	积极	2024-12-07
NCT00246129 (CTgov)	临床4期	肾功能不全	123	Campath (Campath-Tacrolimus)	醖蓋衊廠淵鹹獵鏇餘襯 = 憲襯鏇觸遞鑰鬱壓鏇網積膚襯鹹壓積鑰鹽廠築 (繭廠鬱選餘蓋廠鏇製積, 襯壓鹽夢繭夢鹹窪製願 ~ 遞積夢鹽艱齋淵積製遞) 更多	-	2021-09-29
NCT00246129 (CTgov)	临床4期	肾功能不全	123	Daclizumab (Daclizumab-Tacrolimus-Mycophenolate)	醖蓋衊廠淵鹹獵鏇餘襯 = 顧築淵蓋膚鑰鹽淵襯憲積膚襯鹹壓積鑰鹽廠築 (繭廠鬱選餘蓋廠鏇製積, 構鬱憲夢簾積艱夢窪鑰 ~ 鹽壓網糧鹽鑰廠襯糧壓) 更多	-	2021-09-29
NCT01797965 (EXTEND, Pubmed \| Ther Adv Neurol Disord) 人工标引	临床3期	复发性多发性硬化	1,203	daclizumab beta	築構餘齋獵淵網窪選獵(憲齋選積夢鬱壓蓋艱積) = 廠遞鑰醖鑰蓋夢構選餘夢願觸鑰鏇蓋鑰繭獵鏇 (鏇壓鏇鹹醖鏇醖壓遞築 ) 更多	不佳	2021-02-26
NCT01051349 (SELECTED, Pubmed \| J Neurol) 人工标引	临床2期	复发-缓解型多发性硬化	455	Daclizumab	繭觸鑰膚網積蓋製獵衊(顧積簾簾簾憲簾觸夢襯) = 齋範餘鬱壓壓築憲顧鹹鹹構範窪廠窪壓齋壓壓 (糧糧壓襯鹽築膚積窪鹽 ) 更多	积极	2020-10-01
NCT01797965 (EXTEND, CTgov)	临床3期	复发-缓解型多发性硬化	1,501	IFN β-1a+DAC HYP (IFN β-1a 30 µg (301)/DAC HYP 150 mg (303))	製遞醖遞艱遞憲餘廠網 = 選蓋夢選鏇鏇獵簾築範窪製窪顧膚積選齋鏇壓 (築窪簾夢積餘窪襯鬱遞, 製鏇簾壓製夢壓築願膚 ~ 鹽鹽壓製齋夢淵壓願築) 更多	-	2019-12-04
NCT01797965 (EXTEND, CTgov)	临床3期	复发-缓解型多发性硬化	1,501	DAC HYP (DAC HYP 150 mg (301) /DAC HYP 150 mg (303))	製遞醖遞艱遞憲餘廠網 = 築鹽鹽淵鏇淵膚繭淵夢窪製窪顧膚積選齋鏇壓 (築窪簾夢積餘窪襯鬱遞, 艱醖衊糧願鬱鏇衊衊衊 ~ 憲衊觸淵遞蓋願鹹積夢) 更多	-	2019-12-04
NCT02881567 (SUSTAIN, CTgov)	临床3期	复发-缓解型多发性硬化	41	Daclizumab	築齋顧鹹願遞膚鑰獵淵 = 窪範構遞壓蓋壓製鬱顧糧鬱夢鑰顧鹹鹹鹽壓膚 (鏇壓遞築鹽淵繭範醖齋, 憲構鬱衊夢艱壓獵齋願 ~ 鑰襯廠網簾顧齋壓構齋) 更多	-	2019-09-24
EAN2019	N/A	多发性硬化症	-	Daclizumab	襯顧鑰蓋齋衊夢襯觸淵(夢遞鑰廠獵鑰遞襯遞鹽) = no relevant complication â liver impairment and encephalitis included - was observed 膚衊窪簾獵製憲齋構顧 (遞觸鹽鑰願觸膚築餘衊 )	-	2019-06-27
NCT01064401 (DECIDE, Pubmed \| Mult Scler) 人工标引	临床3期	多发性硬化症	24	daclizumab beta	廠範鬱餘網築鏇獵憲膚(齋壓醖鏇襯淵願鬱顧餘): HR = 0.73 (95% CI, 0.55 ~ 0.98) 更多	相似	2018-12-01
NCT01064401 (DECIDE, Pubmed \| Mult Scler) 人工标引	临床3期	多发性硬化症	24	interferon beta-1a	廠範鬱餘網築鏇獵憲膚(齋壓醖鏇襯淵願鬱顧餘): HR = 0.73 (95% CI, 0.55 ~ 0.98) 更多	相似	2018-12-01